Researchers at Osaka University, Japan have reported a genome editing strategy that allowed mice to produce their own weight ...

Nuvalent Inc. (NASDAQ:NUVL) is one of the best mid cap pharma stocks to buy. On July 21, Nuvalent announced that the first ...

Scientists have gene-hacked mice to produce their own Ozempic-like enzymes, paving a path for humans to do so themselves one day. In a new study published in the journal Communications Medicine, ...

Vivani Medical completed enrollment in its LIBERATE-1 trial, testing a six-month GLP-1 implant for weight management. Top-line results are expected by mid-2025.

Weekly injections of the GLP-1 receptor agonist exenatide (Byetta, Bydureon) did not slow Parkinson's disease progression or improve symptoms, the phase III Exenatide-PD3 trial showed.

Treatment with once-weekly exenatide was not associated with improvements in patients with Parkinson disease, according to findings from a study published in The Lancet.

"Vivani begins exenatide implant trial for obesity in Australia" was originally created and published by Medical Device Network, a GlobalData owned brand.

While exenatide has been associated with certain side effects including changes in kidney function, low blood sugar, and inflammation of the pancreas, it is a significant addition to Amneal's ...

BRIDGEWATER, N.J., November 21, 2024--Amneal Resubmits DHE Autoinjector New Drug Application and Receives U.S. FDA Approval of Exenatide, its First Generic Injectable GLP-1 Agonist ...

A large-scale clinical trial found that intravenous infusion of exenatide, a glucagon-like peptide-1 (GLP-1) analog medication, during heart surgeries involving bypass did not significantly reduce ...

GLORIOUS: Neither Exenatide Nor Restrictive Oxygenation Boost CV Surgery Outcomes The two strategies, used to reduce renal, brain, and heart injury after surgery, were ineffective, but the story isn’t ...

Read the side effects of Exenatide as described in the medical literature. In case of any doubt consult your doctor or pharmacist.